ZYLOXTB (02190) Partners with GL Capital to Make a Strategic Investment in LIFETECH SCI, Committed to Building China's Leading Pan-Vascular and Structural Heart Intervention Platform

On November 6, ZYLOXTB Medical Technology Co., Ltd. (stock code: 02190, hereinafter "ZYLOXTB"), a leading domestic vascular intervention medical technology company, announced a joint strategic investment with GL Capital in LIFETECH SCI (stock code: 01302, hereinafter "LIFETECH SCI"). The two parties' layouts in four major business areasperipheral vascular intervention, neurovascular intervention, aortic vascular intervention, and structural heart diseaseare deeply complementary. Leveraging this advantage, the strategic investment is expected to integrate the two parties' resources in R&D innovation, product portfolios, and global commercialization, laying the foundation for building China's leading pan-vascular and structural heart intervention platform and further enhancing the international competitiveness of Chinese brands. According to the relevant agreements, ZYLOXTB and GL Capital will jointly contribute capital to establish GL Lighthouse Two Investment Limited (hereinafter "Lighthouse Two"), which will subscribe for newly issued shares of LIFETECH SCI for a total of approximately HK$1.482 billion. Upon completion of the transaction, Lighthouse Two will hold approximately 16.7% of the total issued shares of LIFETECH SCI after the share issuance, becoming the single largest shareholder of LIFETECH SCI. Among this, ZYLOXTB intends to contribute approximately HK$889 million, holding 60% of Lighthouse Two's shares. In addition, GL Capital intends to subscribe for 39.8 million newly issued shares of ZYLOXTB at HK$22 per share, representing 10.8% of the company's total shares after this issuance (excluding treasury shares), providing funding support for the company's future further increase in its stake in LIFETECH SCI and overseas business development. The subscription price represents a 13.5% premium over the closing price on the date of the transaction announcement and a 15.4% premium over the average closing price for the five trading days prior to the announcement, fully demonstrating GL Capital's recognition of ZYLOXTB's long-term development. In the future, ZYLOXTB and GL Capital will further increase their shareholding in LIFETECH SCI, accelerate business development, optimize resource allocation, improve operational efficiency, and enhance overall competitiveness and global commercialization capabilities. In addition, ZYLOXTB intends to promote a merger of the two parties in the future to build China's leading pan-vascular and structural heart intervention platform. Core business advantages are complementary, perfecting the layout in pan-vascular and structural heart intervention fields LIFETECH SCI is a leading domestic enterprise in cardio-cerebrovascular and peripheral vascular interventional medical devices, with deep technical accumulation and comprehensive product layout in the aortic intervention and structural heart disease fields. LIFETECH SCI was listed on the Hong Kong Stock Exchange in 2011 and currently holds more than 50 registration certificates cumulatively in China, with 20 products approved to enter the national Innovative Medical Management device "green channel." LIFETECH SCI continues to advance high-quality global intellectual property layout, having cumulatively filed 2,608 valid patent applications as of June 30, 2026, of which 1,370 have been granted. In the aortic intervention field, LIFETECH SCI has taken the lead in building the world's most advanced and complete total endovascular aortic treatment solution, comprehensively covering the three key technical areas of endovascular reconstruction of arch branches, visceral branches, and internal iliac arteries, widely praised by domestic and international clinicians and occupying a leading share in the domestic market. Multiple globally pioneering products, including the G-Branch thoracoabdominal aortic stent graft system, the Concave Supra integrated three-branch arch reconstruction system, and the SureCham single-branch aortic arch stent graft system, focus on unmet clinical needs and continue to lead technological innovation in endovascular aortic treatment. In the structural heart disease field, LIFETECH SCI's core products include the LAmbre and LAxible two generations of left atrial appendage occluders and three generations of congenital heart disease occluder series products, continuously meeting different treatment needs through differentiated product strategies and maintaining a long-term important position in the domestic market. ZYLOXTB is a leading domestic vascular intervention medical technology company, with two major brands, "Zylox Medical" and "Tongqiao Medical," focusing on the peripheral vascular intervention and neurovascular intervention fields, respectively. As one of the few domestic enterprises capable of providing full product solutions in both fields, the company has developed complete platform capabilities covering R&D innovation, product development, and large-scale commercialization. From 2025 to date, ZYLOXTB has added 6 products entering the national Innovative Medical Management device "green channel." Leveraging an efficient operating system and large-scale commercialization advantages, ZYLOXTB has covered more than 3,500 hospitals in China and achieved commercialization in 70 countries and regions overseas, with global operational capabilities continuing to strengthen. This strategic investment will fully leverage the complementary advantages of both parties in core technologies, product layouts, and commercialization capabilities, promote deep integration of advantageous resources, build a pan-vascular and structural heart intervention platform covering four core business areas, further expand business scale, strengthen industry leadership, and enhance global market competitiveness. Accelerating global business expansion, enhancing the international market competitiveness of Chinese brands In recent years, ZYLOXTB has continued to advance its internationalization strategy, with international business maintaining strong growth. In the first half of 2026, the company's international business revenue grew 349.3% year-on-year, with products commercialized in 70 countries and regions overseas and a global channel network covering more than 135 countries and regions. ZYLOXTB continues to deepen its layout in key markets such as Europe, Latin America, and Asia, enhancing global market access and commercialization capabilities. Through the strategic acquisition and integration of German vascular intervention medical device company optimed, the company has further strengthened its localized operations in Europe. LIFETECH SCI has a mature global sales network and international operational foundation, currently with 7 overseas subsidiaries and a sales network covering nearly 120 countries and regions worldwide. In full-year 2025, LIFETECH SCI's overseas revenue was nearly RMB400 million, up approximately 14.4% year-on-year, accounting for nearly 30% of total revenue. Among this, the European and Asian markets are its main sources of overseas revenue, reflecting strong international market competitiveness. This strategic investment will create conditions for both parties to further integrate global R&D and marketing resources, fully leverage their complementary advantages in product portfolios, market channels, and operating systems, enhance the international competitiveness of Chinese brands, and accelerate the building of a globally competitive Chinese pan-vascular and structural heart intervention platform. Dr. Zhao Zhong, Chairman of ZYLOXTB, said, "This strategic investment is an important milestone for ZYLOXTB in building China's leading pan-vascular and structural heart intervention platform. Through complementary advantages with LIFETECH SCI, ZYLOXTB will further expand from the peripheral and neurovascular intervention fields into the aortic intervention and structural heart disease fields, forming a more complete business layout and expanding long-term development space. At the same time, leveraging ZYLOXTB's mature operating system and global layout, we are confident in further leveraging business synergies and scale advantages, enhancing overall competitiveness, and accelerating our march toward becoming a globally leading Innovative Medical Management technology enterprise." Mr. Li Zhenfu, Founding Partner and CEO of GL Capital, said, "GL Capital has been deeply engaged in China's healthcare industry for many years and has always been committed to accompanying outstanding enterprises as they grow through long-term capital and deep empowerment. We have long been optimistic about the development prospects of China's vascular intervention medical device industry and the global growth potential of Chinese Innovative Medical Management device enterprises. Taking this strategic investment as an opportunity, GL Capital will join hands with advantageous resources from all parties to help accelerate the achievement of the common strategic goal of building an internationally competitive pan-vascular and structural heart intervention platform. In the future, we will continue to leverage our capital and industry resource advantages to support enterprises in enhancing competitiveness and accelerating global development." Mr. Xie Yuehui, founder of LIFETECH SCI, said, "This introduction of strategic investment demonstrates the industry's and capital's high recognition of LIFETECH SCI's technological innovation capabilities, market leadership, and long-term growth value. LIFETECH SCI and ZYLOXTB are highly complementary in business layout, product portfolios, and market channels. This strategic move will open a new development chapter for LIFETECH SCI, promote deep synergy of both parties' products, technologies, and advantageous resources, and further consolidate its industry leadership. I will serve as a senior advisor to LIFETECH SCI, relying on nearly thirty years of industry experience to continue empowering the company's long-term development and accompanying LIFETECH SCI toward a higher stage of development."